Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 18, 2020 (7 years ago)

Phentermine Hydrochloride Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Phentermine Hydrochloride Capsules, USP 15mg, 100-count bottles, Distributed by: Aurobindo Phama USA, Inc. Dayton, NJ 08810, NDC 13107-105-01

Affected NDC 13107-0105-01

Compare with the code on your package — it is the most precise check available.

Drug: Phentermine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Phentermine
Phentermine Hydrochloride
NDC 13107-0105
15 mg/1 Capsule
Oral
Aurolife Pharma, LLC Rx · CIV
Recalling firm
Aurobindo Pharma USA Inc.
NDC code
13107-105-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1236-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Phentermine recalls

See all
Class II · Moderate risk

Phentermine

cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.

Terminated Stability / shelf life Calvin Scott & Company, Inc. NDC 00527-0597-10 D-0011-2021
Class II · Moderate risk

Phentermine HCL Blue Speckled tablets

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 10702-0025-10 D-1532-2020

Other recalls by Aurobindo Pharma USA Inc.

All 2020 recalls
Class II · Moderate risk

Acetaminophen Tablets

cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).

Ongoing Failed specification Aurobindo Pharma USA Inc NDC 72288-405-10 D-0471-2025
Class II · Moderate risk

Nebivolol Tablets

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc D-0149-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-833-30 D-0079-2025